Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00258635 · ClinicalTrials.gov registry record · Phase 2
Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test
A Phase 2 study, sponsored by Allergy Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT00258635 is a Phase 2 study that has completed, run by Allergy Therapeutics. The registered enrollment target is 69 participants.
The verdict
NCT00258635, a Phase 2 study, has completed, sponsored by Allergy Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the immunological differences between three RagweedMATAMPL treatment arms compared to placebo with respect to immunoglobulin levels. In addition, the study will assess the reduced allergenicity of modified Ragweed Pollen contained in RagweedMATAMPL compared to unmodified native allergen using skin prick testing.
Interventions
- BIOLOGICAL RagweedMATAMPL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-08-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00258635
The ClinicalTrials.gov registry entry for NCT00258635 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergy Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RagweedMATAMPL is the first listed.
NCT00258635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00258635 about?
NCT00258635 is a clinical study titled "Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test". The purpose of this study is to assess the immunological differences between three RagweedMATAMPL treatment arms compared to placebo with respect to immunoglobulin levels. In addition, the study will assess the reduced allergenicity of modified Ragweed Pollen contained in RagweedMATAMPL compared to...
What is the current status of trial NCT00258635?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2005-11. Estimated completion is 2006-08-07.
What interventions are being tested in trial NCT00258635?
The interventions under investigation include: RagweedMATAMPL (BIOLOGICAL).
Who is sponsoring clinical trial NCT00258635?
This trial is sponsored by Allergy Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.